MARKET

BCDAW

BCDAW

BIOCARDIA
NASDAQ

Real-time Quotes | Nasdaq Last Sale

1.100
0.00
0.00%
Opening 09:30 05/07 EDT
OPEN
--
PREV CLOSE
1.190
HIGH
--
LOW
--
VOLUME
0
TURNOVER
--
52 WEEK HIGH
3.500
52 WEEK LOW
0.5150
MARKET CAP
2.03M
P/E (TTM)
-0.6604
1D
5D
1M
3M
1Y
5Y
BRIEF-Biocardia Signs Agreement With Leading Japanese Biotechnology Company For Catheter Biotherapeutic Delivery Product Candidates
reuters.com · 04/26 12:49
BRIEF-Biocardia Inc Says Co & Lincoln Park Capital Fund Entered Purchase Agreement And Registration Rights Agreement
reuters.com · 03/29 21:24
BRIEF-BioCardia Signs Agreement With Leading Japanese Pharmaceutical Company For Catheter Biotherapeutic Delivery Product Candidates
reuters.com · 02/23 13:13
BRIEF-BioCardia Update On Cell Therapy Product Development And 2021 Milestones
reuters.com · 02/02 13:37
BioCardia Issued New Patent for Delivery of Cardiac Cell Therapy Through Wrist Artery
Technology May Enable Same-Day Outpatient Cell Therapy ProceduresSAN CARLOS, Calif., Sept. 29, 2020 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [Nasdaq: BCDA] a leader in the development of comprehensive solutions for cardiovascular regenerative therapies, today ...
GlobeNewswire · 09/29/2020 12:00
BioCardia to Present at the LD Micro 500 Virtual Conference on September 1, 2020
SAN CARLOS, Calif., Aug. 26, 2020 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [Nasdaq: BCDA], a leader in the development of comprehensive solutions for cardiovascular regenerative therapies today announced that Peter Altman, Ph.D., Biocardia’s Chief Executive Of...
GlobeNewswire · 08/26/2020 11:00
BioCardia Reports Second Quarter 2020 Financial Results and Business Highlights
SAN CARLOS, Calif., Aug. 13, 2020 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [NASDAQ: BCDA], a leader in the development of comprehensive solutions for cardiovascular regenerative therapies, today reported financial results and business highlights for the second...
GlobeNewswire · 08/13/2020 11:00
BioCardia To Conduct Mid-Year Conference Call and Corporate Update August 13, 2020
SAN CARLOS, Calif., Aug. 07, 2020 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [NASDAQ:BCDA], a leader in the development of comprehensive solutions for cardiovascular regenerative therapies, today announced it will be conducting a mid-year corporate update confer...
GlobeNewswire · 08/07/2020 12:00
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of BCDAW. Analyze the recent business situations of BIOCARDIA through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
EPS
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+2.20%
Pharmaceuticals & Medical Research
+1.09%
Key Executives
Chairman/Independent Director
Simon Stertzer
President/Chief Executive Officer/Director
Peter Altman
Chief Financial Officer
David McClung
Vice President - Operations
Phil Pesta
Other
Sujith Shetty
Director
Krisztina Zsebo
Independent Director
Jim Allen
Independent Director
Andrew Blank
Independent Director
Fernando Fernandez
Independent Director
Richard Krasno
Independent Director
Jay Moyes
No Data
About BCDAW
BioCardia, Inc. is a clinical-stage regenerative medicine company engaged in developing therapeutics for cardiovascular diseases. The Company's therapeutic portfolio consists of the CardiAMP and CardiALLO cell therapies. The Company's lead therapeutic candidate is the CardiAMP Cell Therapy System (CardiAMP) and focuses on the Phase III trial for CardiAMP in ischemic systolic heart failure. The Company's CardiALLO Cell Therapy System (CardiALLO), is an allogeneic off the shelf mesenchymal stem cell product candidate from other donors. The Company’s products also include Helix Biotherapeutic Delivery System and Morph Deflectable Guide and Sheaths Products.

Webull offers kinds of BioCardia Inc stock information, including NASDAQ:BCDAW real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, BCDAW stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading BCDAW stock methods without spending real money on the virtual paper trading platform.